

## Devyser secures a major tender worth SEK 61.8 M in Udine, Italy

Devyser, a leading provider of advanced genetic testing solutions, has been awarded a significant new tender in Udine, Italy, valued at SEK 61.8 million over a 36-month period. Representing a 10% increase from the previous agreement, the expanded contract highlights Devyser's continued growth and trusted reputation in the European diagnostics market.

The tender includes Devyser's portfolio of Next-Generation Sequencing (NGS) and Fragment Analysis (FA) products. These products support a wide range of genetic testing needs and offer labs in Udine an end-to-end, streamlined diagnostics experience. Collectively, these products support key diagnostic areas, including hereditary diseases and oncology.

Winning this tender significantly validates Devyser's ability to meet diverse and complex diagnostic needs with a unified, high-quality offering.

"This contract further solidifies Devyser's position as a **true one-stop shop** for genetic testing labs," added Theis Kipling, CCO. "Our comprehensive solutions and seamless workflows — combined with expert support and training — are designed to simplify lab operations and accelerate high-quality diagnostics. We're proud to support labs in Udine with reliable, efficient solutions that enable confident clinical decisions."

This contract strengthens Devyser's strategic presence in Italy — one of Europe's most advanced markets for molecular diagnostics — and demonstrates the company's growing role as a partner to regional healthcare systems.

### For more information, please contact:

Fredrik Dahl, interim CEO

E-mail: [ir@devyser.com](mailto:ir@devyser.com)

Telephone: +46 8 562 158 50

Theis Kipling, CCO

E-mail: [ir@devyser.com](mailto:ir@devyser.com)

Telephone: +46 8 562 158 50



**PRESS RELEASE**  
24 April 2025 11:00:00 CEST

### **About Devyser**

Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.

For more information, visit [www.devyser.com](https://www.devyser.com).